For patients with relapsed blood cancers, treatment options can become increasingly limited after chemotherapy, targeted therapy, immunotherapy, or stem cell transplantation. However, CAR-T cell therapy has changed that landscape.
Today, CAR-T cell therapy in India is available for selected patients with specific B-cell malignancies, including certain forms of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphomas. However, CAR-T is not a treatment that every blood cancer patient can receive. Eligibility depends on the cancer type, previous treatments, disease status, overall health, and the specific CAR-T product available at the treating centre.
What Is CAR-T Cell Therapy?
CAR-T stands for chimeric antigen receptor T-cell therapy. It is a form of cellular immunotherapy in which T cells, a type of white blood cell involved in immune defence, are collected from the patient and genetically modified in a specialised laboratory.
The modified cells are designed to recognize a particular antigen on cancer cells. They are then expanded and returned to the patient through an infusion.
For example, NexCAR19 is an indigenous CD19-directed CAR-T therapy developed in India. It received marketing authorisation from India’s Central Drugs Standard Control Organisation (CDSCO) in 2023. Clinical studies leading to its development included patients with B-cell leukemia and lymphoma.
The important point is that CAR-T is a personalized treatment, not simply another chemotherapy drug.
Who May Benefit From CAR-T Therapy?
Eligibility must be determined by a hematologist or medical oncologist after reviewing the patient’s complete medical history. Depending on the product and regulatory indication, CAR-T may be considered for patients with certain:
- Relapsed or refractory B-cell acute lymphoblastic leukemia
- Relapsed or refractory B-cell lymphomas
- Other blood cancers where an approved CAR-T product or clinical trial is appropriate
This is why searching for the best hospital for CAR-T therapy in India should not begin with hospital rankings alone. The more useful question is: Which centre has the appropriate CAR-T program, product, specialists, laboratory infrastructure and experience for this particular cancer?
Patients should also ask whether the therapy is being offered under an approved indication or as part of a clinical trial.
CAR-T Cell Therapy in India: What Patients Should Know
For families researching CAR-T therapy for leukemia in India, the first step should be a detailed eligibility assessment.
Doctors may review:
- The exact leukemia subtype
- Whether the cancer has relapsed or become refractory
- Previous chemotherapy and other treatments
- Bone marrow findings
- Immunophenotyping and target-antigen status
- Organ function and overall fitness
- Active infections and other medical conditions
- Previous stem cell transplantation, where applicable
CAR-T therapy is particularly significant in B-cell malignancies because therapies targeting antigens such as CD19 can direct engineered T cells toward malignant B cells.
Clinical data from the early Indian NexCAR19 trials demonstrated responses in patients with advanced B-cell leukemia and lymphoma, although individual outcomes can vary considerably.
A response should not be interpreted as a guaranteed cure. Some patients achieve durable remission, while others may experience persistent disease or relapse.
How Does the CAR-T Treatment Process Work?
The treatment involves several stages and may take considerably longer than a conventional infusion-based therapy.
- Medical evaluation
The treating team first determines whether CAR-T is clinically appropriate. Additional testing may be required before the patient is accepted for treatment.
- T-cell collection
The patient’s blood is processed through a procedure called leukapheresis. Following that, T cells are collected and sent for manufacturing.
- Cell manufacturing
The collected T cells are modified so they express the required chimeric antigen receptor. They are then multiplied to produce the treatment dose.
- Preparation before infusion
Depending on the treatment protocol, the patient receives lymphodepleting chemotherapy before the CAR-T cells are infused.
- CAR-T cell infusion
The manufactured cells are returned to the patient through an intravenous infusion.
- Close monitoring
The period following infusion is particularly important because CAR-T can produce serious immune-related complications. Therefore, patients in India need monitoring by a team experienced in cellular therapy.
What Are the Major Risks?
CAR-T therapy can produce side effects. Two complications that patients should understand before treatment are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
CRS can cause fever, rapid heartbeat, low blood pressure, and breathing difficulties. Severe cases can become life-threatening.
Neurological complications may include confusion, difficulty speaking, altered consciousness or seizures. Patients may also experience infections, prolonged low blood counts and other complications depending on the therapy and individual circumstances.
This explains why CAR-T should be administered in a centre with appropriate monitoring.
CAR-T Therapy Cost in India
One of the most searched questions is CAR-T therapy cost in India. There is no single price applicable to every patient.
A reported figure in 2025 placed the overall cost of CAR-T treatment in India at approximately ₹50 lakh, including hospital-related expenses, but actual costs can vary according to the CAR-T product, hospital, clinical condition, supportive treatment, length of stay, and complications.
Therefore, families should request a written estimate that distinguishes between:
- CAR-T product/manufacturing charges
- Cell collection
- Hospitalisation
- Lymphodepleting chemotherapy
- Laboratory investigations
- Medicines
- Specialist fees
- Management of complications
- Intensive care, if required
- Follow-up investigations
CAR-T Treatment for International Patients
For patients considering CAR-T cell therapy in India, preparation should begin before booking a flight.
International families can typically start by sharing medical records, pathology reports, imaging, treatment history, and recent laboratory results with an Indian oncology team. A specialist can then determine whether further testing or an in-person assessment is required.
Curebridge also provides support for international oncology patients, including hospital coordination, visa assistance, travel planning, accommodation, and post-treatment coordination.
Therefore, obtaining a medical opinion before travelling is important. Since CAR-T is highly specialised, not every patient who travels to India will be eligible for the therapy.
Questions to Ask Before Choosing CAR-T
Before proceeding, patients and families should ask the treating centre:
- Is CAR-T approved for my specific cancer and treatment situation?
- Which CAR-T product is being considered?
- What evidence supports its use for my cancer?
- What tests are required before treatment?
- How long will manufacturing take?
- How long might hospitalisation last?
- What complications should we prepare for?
- What is included in the cost estimate?
- What happens if the disease progresses after CAR-T?
- What follow-up will be required after returning home?
These questions can help families make decisions based on the patient’s actual clinical situation.
The Bottom Line
CAR-T therapy represents a major development in blood cancer treatment, particularly for selected patients whose disease has returned or stopped responding to conventional therapies.
But CAR-T is not a universal solution, and affordability alone should not determine where or whether treatment takes place. Eligibility, the appropriate CAR-T product, the treating team’s experience, emergency support and long-term follow-up are equally important.
Therefore, obtaining a specialist opinion before travelling makes the process more focused and practical.
Contact us for oncology consultations and treatment coordination in India.
FAQs
- Is CAR-T cell therapy available in India?
Yes. India has approved CAR-T products, including the indigenous NexCAR19, for specific indications. Availability depends on the patient’s cancer type and eligibility.
- Is CAR-T therapy suitable for all leukemia patients?
No. Eligibility depends on the leukemia subtype, disease status, previous treatments, target-antigen expression, and the specific CAR-T product or clinical trial.
- What cancers can CAR-T therapy treat?
CAR-T has established applications in several B-cell blood cancers. Specific indications vary by product and regulatory approval.
- How much does CAR-T therapy cost in India?
A reported 2025 estimate was around ₹50 lakh including hospital-related costs, but actual expenses vary significantly between patients and treatment centres.
- How long does CAR-T treatment take?
The overall process includes evaluation, cell collection, manufacturing, preparation, infusion and monitoring. The exact timeline varies by patient and treatment protocol.
Leave a Reply